Literature DB >> 7988421

Insulin delivery in nosedrops: new formulations containing alkylglycosides.

D J Pillion1, J A Atchison, C Gargiulo, R X Wang, P Wang, E Meezan.   

Abstract

Insulin was administered to rats via nosedrops in the presence or absence of various alkylglycosides; systemic insulin absorption was measured as a fall in blood D-glucose concentration in animals made hyperglycemic by xylazine/ketamine anesthesia. Nosedrops (0.04 ml) containing alkylglycosides or regular porcine insulin alone were without effect. Nosedrops containing both a small amount of alkylglycoside (0.03-0.50%) and insulin (2 U regular porcine) caused a rapid decrease in blood D-glucose levels and a concomitant increase in serum immunoreactive insulin levels. The maximal hypoglycemic response was observed between 60 and 120 min after delivery of nosedrops. Decylmaltoside was less effective at enhancing systemic insulin absorption than dodecylmaltoside, tridecylmaltoside, or tetradecylmaltoside, whereas octylmaltoside was totally ineffective. Dodecylsucrose, a compound which differs from dodecylmaltoside only in one carbohydrate residue, had a similar effect on blood D-glucose values when it was included in the nosedrop formulation with insulin. Decylsucrose was considerably less potent than dodecylsucrose at enhancing systemic absorption of insulin. Nonylglucoside was effective at promoting insulin absorption from nosedrops only when used at higher doses (0.25-0.50%), whereas heptylglucoside and hexylglucoside were ineffective. These results indicated that nosedrops containing insulin plus an extremely low concentration (0.03%) of an absorption-enhancing agent such as tetradecylmaltoside can be used to lower blood D-glucose values.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988421     DOI: 10.1210/endo.135.6.7988421

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: independence of surfactant action from multimer dissociation.

Authors:  D J Pillion; S Hosmer; E Meezan
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

4.  Mutual inhibition of the insulin absorption-enhancing properties of dodecylmaltoside and dimethyl-beta-cyclodextrin following nasal administration.

Authors:  F Ahsan; J J Arnold; E Meezan; D J Pillion
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

5.  Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats.

Authors:  F Ahsan; J Arnold; E Meezan; D J Pillion
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

6.  Nasal absorption of mixtures of fast-acting and long-acting insulins.

Authors:  Dennis J Pillion; Michael D Fyrberg; Elias Meezan
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

7.  Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin.

Authors:  Alamdar Hussain; Tianzhi Yang; Abdel-Azim Zaghloul; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

8.  Effect of Nonionic Surfactants (Dodecyl Maltoside and Polysorbate 20) on Prevention of Aggregation and Conformational Changes of Recombinant Human IFNβ_1b Induced by Light.

Authors:  Najmeh Mahjoubi; Ahmad Fazeli; Rassoul Dinarvand; Mohammad Reza Khoshayand; Maryam Shekarchi; Mohammad Reza Fazeli
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.